Drug-Eluting Stents for Chronic Total Occlusion
stent (SES) implantation compared with 41% after bare-metal stent (BMS) implantation. 12 Although DESs have shown a significant decrease in the need for repeated revascularization and restenosis rate, the majority of the data regarding the impact of DESs in the field of CTO-PCI are for SES, and comparisons of efficacy are confined only to that with BMS. 8- 12 Comparative results of angiographic and long-term clinical efficacy of first-generation DESs in CTO lesions have recently been obtained using registry data, 13 but there has been no randomized trial regarding the direct comparison of angiographic and clinical outcomes among currently approved DESs in patients with CTO lesion. The zotarolimus-eluting stent (ZES) is a second-generation DES consisting of zotarolimus; a low-profile cobalt alloy stent; and a biocompatible polymer, which reduces the rate of restenosis and need for repeated revascularization in the PCI of de novo stenotic lesions, as compared to a BMS. 14, 15 The more rapid elution kinetics of zotarolimus from the phosphorylcholine polymer of the ZES may produce different biological activities in the CTO lesion, especially in neointimal hyperplasia and re-endothelialization, as compared with the slower release of sirolimus from the polyethylene-co-vinyl acetate/poly n-butyl methacrylate co-polymer of SES. 16- 19 We therefore conducted a prospective, randomized, multicenter trial comparing the angiographic and clinical efficacy and safety of the ZES implantation with SES implantation in patients with CTO lesion.
Methods

Subjects
The CAtholic Total Occlusion Study (CATOS) trial was a prospective, randomized, single-blind, multi-center trial (8 centers in Korea) in which 160 patients with CTO lesion were recruited. Enrollment of subjects began in October 2007 and was completed in March 2010. Patients were considered eligible if they were at least 18 years of age and the estimated duration of the total coronary occlusion was at least 1 month prior to the procedure, which was documented by clinical history, angiographic evidence, or both. CTO was defined by the absence of antegrade flow of contrast distal to the occlusion (Thrombolysis In Myocardial Infarction [TIMI] flow grade 0) or only minimal flow of contrast distal to the occluded vessel (TIMI flow grade 1) with an estimated duration ≥1 month. 12, 13 Patients were excluded for the following reasons: Q wave or non-Q wave myocardial infarction (MI) within the preceding 30 days in the region of the artery to be dilated; a documented left ventricular ejection fraction ≤35%; impaired renal function (creatinine >3.0 mg/dl); a prior stent within 5 mm of the target lesion; known allergies to aspirin, clopidogrel, ticlopidine, or heparin; participation in another trial; and factors making longterm follow-up difficult or unlikely, including life expectancy <1 year. Lesion-related exclusion criteria were as follows: reference diameter of the target vessel at the proximal lesion site <2.5 mm on visual estimation; visible thrombus adjacent to the occlusion site on angiography; significant left main coronary artery disease; totally occlusive diffuse in-stent restenosis; and occlusion of venous or arterial bypass grafts.
The study was conducted according to the principles of the Declaration of Helsinki and was approved by the Ethics Committees at each participating center. Informed consent was obtained from each patient before the procedure.
Randomization and Stent Implantation
The PCI was performed according to current standard intervention techniques. Before or at the time of the procedure, all patients were treated with a loading dose of at least 300 mg of clopidogrel and 100 mg of aspirin. At the start of the procedure, patients received a single dose of unfractionated heparin (80-120 U/kg). Glycoprotein IIb/IIIa inhibitors were given at the discretion of the operator. After crossing a guidewire through the occluded lesion and before the initial balloon dilatation, patients were randomly assigned to receive a ZES or SES by a Web-based computer-generated allocation system. After the intervention, anti-platelet therapy was continued and consisted of ≥100 mg of aspirin once daily indefinitely and 75 mg of clopidogrel once daily for at least 12 months.
Angiographic Follow-up Protocol and Quantitative Analysis
Follow-up angiography was routinely performed at 9 months after the index procedure or earlier if there were clinical signs of restenosis, such as recurrent angina symptoms, a positive exercise test, or abnormal nuclear imaging. Coronary angiograms were digitally recorded at baseline, immediately after the procedure, and at the 9-month follow-up and were assessed offline at the quantitative angiographic core laboratory with an automatic edge-detection system (CAAS II; Pie Medical, Maastricht, The Netherlands) by 2 independent experienced operators. Quantitative coronary angiography (QCA) analysis involved the in-stent and in-segment areas, including the stented segment, and 5-mm margins proximal and distal to the stent. On the 9-month follow-up angiography, in-segment binary restenosis was defined as >50% residual diameter stenosis (DS); in-segment late luminal loss (LL) was also defined as a subsequent decrease in the minimal luminal diameter (MLD) of the treated artery, including the stented segment, and 5-mm margins proximal and distal to the stent.
Intravascular Ultrasound (IVUS) Protocol and Quantitative
Analysis IVUS was performed, after 0.2 mg intracoronary nitroglycerin was given, using a motorized transducer pullback (0.5 mm/s) and commercial scanner (SCIMED Boston Scientific, Maple Grove, MN, USA) consisting of a 30-MHz transducer rotating at 1,800 r.p.m. within a 3.2-Fr imaging sheath. Volumetric IVUS analysis was performed by an independent core laboratory (Asan Medical Center, Seoul, Korea). All images were reviewed by 2 independent observers, and adjudication of opinion was based on the consensus of these observers.
Volumetric measurements were performed using planimetry software (echoPlaque, Indec Systems, Santa Clara, CA, USA) as previously described. 20 Intimal hyperplasia (IH) cross-sectional area (CSA) was measured at the narrowest lumen and the following parameters were used: stent CSA, lumen CSA, IH CSA, and percent IH CSA. IH volume was also calculated as the stent minus lumen volume, and the percentage of IH volume obstruction was calculated as the IH volume divided by stent volume. Incomplete stent apposition (ISA) was identified as ≥1 struts clearly separated from the intimal surface of the arterial wall with evidence of blood speckles behind the strut but not overlapping a side branch. 21 
Study Endpoints
Clinical follow-up was performed at 1, 6, 9, and 12 months with angiographic follow-up at 9 months. The primary endpoint was the in-segment binary restenosis rate at the 9-month follow-up, which was assessed by an independent core laboratory. Key secondary endpoints were TVF, defined as a composite of cardiac death, MI, and target vessel revascularization (TVR), and definite/probable stent thrombosis (ST) at 12 PARK HJ et al. months according to the Academic Research Consortium definitions. TVR was defined as percutaneous or surgical revascularization of stented lesion including 5-mm margin segments and more proximal or distal, newly developed lesion if the percent DS was >50% on QCA in the presence of ischemic signs or symptoms.
Statistical Analysis
This randomized study was designed to determine if the primary endpoint (in-segment binary restenosis at 9 months) for ZES was non-inferior to that of SES. The sample size estimation was based on a non-inferiority test using the FarringtonManning approach at an α=0.05 (1-sided) significance level with 80% statistical power to reject the null hypothesis of inferiority. 22 Assuming an expected in-segment binary restenosis rate for ZES and SES to be 11.0% (as found in the PRISON II study 12 ) and a non-inferiority margin of 15.0% with at least 90% angiographic follow-up, a total sample size of 160 enrolled patients was required. Sample size calculations were performed using NCSS-PASS (NCSS, Kaysvelle, UT, USA).
Analysis between groups for statistically significant differences in the categorical data was performed using the chisquare test and Fisher's exact test. The continuous variables are presented as mean ± SD, and they were compared using Student's t-test. All randomized patients were included in the clinical endpoint analyses according to the intention-to-treat principle. Analysis of angiographic endpoints was restricted to patients with follow-up angiography. Statistical analyses were performed using SPSS version 15.0 (SPSS, Chicago, IL, USA). For all analyses, P<0.05 was considered statistically significant.
Results
Baseline Clinical and Procedural Characteristics
A total of 174 patients were screened for this study, of whom 9 patients declined to participate or met the exclusion criteria, and 5 were excluded because the lesion could not be crossed by a guidewire. A total of 160 patients were enrolled and randomly assigned to receive either a ZES or SES. The clinical characteristics were similar in both groups except for total and low-density lipoprotein cholesterol levels ( Table 1) . The angiographic and procedural characteristics are listed in Table 2 . There were no significant differences in the extent of coronary artery disease, occluded lesion location, vessel size, lesion length, or collateral fillings between the groups. Although the Table 2 ).
QCA and IVUS
The angiographic follow-up rate was 89% in the ZES group and 91% in the SES group. Post-procedural MLD and percent DS were similar between the ZES and SES treatment arms ( Table 4 ). In addition, IH volume was 74±53 mm 3 for ZES and 25± 29 mm 3 for SES (P=0.004), and percent IH volume obstruction was 20.9±12.5% for ZES and 7.5±7.7% for SES (P=0.002; Table 4 ). ISA immediately after the procedure was similar in both groups (6.3% vs. 10.0%, P=0.385), but late-acquired ISA was present in 2 ZES patients (6.5%) and in 9 SES patients (25.7%; P=0.036). Data given as mean ± SD or n (%). *Significant if percent diameter stenosis >50%. Abbreviations see in Table 1 . Data given as mean ± SD or n (%). Abbreviations see in Table 1 .
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Clinical Outcomes
All randomized patients completed the 12-month clinical follow-up. The key secondary endpoint, TVF at 12 months, was similar in ZES and SES patients (10.0% for ZES and 17.5% for SES, P=0.168; Table 5 ; Figure) . There were no significant between-group differences in the rate of cardiac death, MI, or TVR, nor in the rate of ST during the 12-month clinical follow-up ( Table 5 ).
Discussion
In this study, we demonstrated that the ZES was non-inferior to the SES in patients with CTO-PCI with respect to the primary endpoint, angiographic in-segment binary restenosis rate at 9 months, which occurred in 14.1% and in 13.7% of patients, respectively (P<0.001 for non-inferiority). There were no significant between-group differences in the rate of TVF (10.0% vs. 17.5%, P=0.168) nor in the rate of ST (0.0% vs. 1.3%, P=0.316) during the 12-month clinical follow-up. These findings suggest that ZES might have comparable efficacy and safety relative to SES and thus be a good option for the treatment of CTO. This study is the first randomized trial involving a direct comparison of angiographic and clinical outcomes between ZES and SES for the treatment of CTO. Histopathologically, CTO is a complex lesion containing variable amounts of collagen, lipids, calcifications, and intraluminal microchannels. 23 Fragmented internal elastic lamina and disruption of the media are seen at proximal fibrous caps at the entrance of the CTO, as well as prominent macrophage infiltration, particularly in perivascular regions. 24 Therefore, a CTO has lower elasticity and tension than non-occluded vessels and is more vulnerable to vessel injury. 23, 24 By the nature of its complexity, the PCI in CTOs is characterized by a limited primary success rate and higher TVF rate as compared to interventions of stenosed but patent lesions. 25 Recently, the use of DESs has resulted in restenosis rates similar to that in nonoccluded arteries, which has led to increased attempts at recanalization. 8- 12 Hoye et al first reported, after studying 56 patients treated with SES for CTO (the subgroup study from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital registry [RESEARCH] ), that the binary restenosis rate was 9.1% at the 6-month angiographic follow-up, which was significantly lower as compared to the historical data for BMS. 8 In a retrospective analysis of 122 patients who underwent revascularization in CTO lesions with SES, the restenosis rate was significantly lower in the SES than in the BMS group at the 6-month follow-up (9.2% vs. 33.3%, P<0.001). 9 One ran- Data given as mean ± SD or (%) n. CSA, cross-sectional area; IH, intimal hyperplasia. Other abbreviations see in Table 1 . The ZES is a second-generation DES consisting of zotarolimus; a low-profile cobalt alloy stent; and a biocompatible phosphorylcholine polymer. 14 A randomized trial comparing the ZES with the SES in patients with de novo stenotic lesions showed that the in-segment LL (0.34±0.44 mm vs. 0.13±0.32 mm, P<0.001) and binary restenosis rate (11.7% vs. 4.3%, P=0.04) were significantly higher in the ZES group than in the SES group at the 8-month angiographic follow-up. 26 IVUS analysis also showed that percent IH volume obstruction (16.1±11% vs. 2.7±3%, P<0.001) was significantly greater with ZES compared with SES. 26, 27 Limited data are available, however, regarding the direct comparison of angiographic and clinical outcomes between ZES and SES in patients with CTO-PCI. In the present study, we hypothesized that the more rapid elution kinetics of zotarolimus from the biostable polymer of ZES might have different biological activities in CTO lesions, especially in neointimal hyperplasia and re-endothelialization as compared with those of SES. [16] [17] [18] [19] As a result, the difference of in-segment binary restenosis rate at 9 months between the ZES and SES groups was only 0.4%, and the 1-tailed 95%CI upper limit was lower than the non-inferior margin of 15% (95%CI: -11.9 to 12.8), even though the insegment binary restenosis rate of the SES group was somewhat higher than that reported in previous studies. 8 -13 In addition, there were no significant between-group differences in the rate of TVF (10.0% vs. 17.5%, P=0.168) nor in the rate of ST (0.0% vs. 1.3%, P=0.316) during the 12-month clinical follow-up. These findings suggest that the ZES may be as effective and safe as the SES and thereby a good treatment option in patients undergoing PCI for CTO with DESs. In this study, there were significant differences in IH CSA and volume, with higher IH in ZES than SES during the 9-month IVUS follow-up. It remains an open question, however, as to whether there is acceptable range of neointimal growth, even though the IH obstruction presumably represents the power of a DES for neointimal inhibition. 27 In addition, it is difficult to generalize from these findings because these parameters are not the primary endpoints of the present study and only 41% of patients underwent 9-month IVUS follow-up because it was not mandated by protocol.
Late-acquired ISA may be the consequence of chronic inflammation and delayed healing of DESs, resulting in tissue necrosis and erosion around the stent. 28 A preclinical study showed that there was less inflammation with the ZES than with the SES or paclitaxel-eluting stents, and that all struts of the ZES were covered by neointimal tissue. 18 The ENDEAVOR III study also showed that the incidence of late-acquired ISA in the ZES group was significantly lower than in the SES group in patients with de novo native coronary lesions (0.5% vs. 5.9%, P=0.02). 27 Of course, in CTO lesions, which might Figure. Landmark analysis for the cumulative rate of target vessel failure (cardiac death, myocardial infarction, and target vessel revascularization) vs. type of drug-eluting stent at 6- and 12-month follow-up after percutaneous coronary intervention for chronic total occlusion. PARK HJ et al.
be more vulnerable to the toxicity of eluted drugs and inflammatory reactions of stent polymers because of the pathologic characteristics, there is the potential for an upward drift in the incidence of late-acquired ISA and, thus, greater differences between ZES and SES might become apparent. As expected, in the present study late-acquired ISA was relatively uncommon in the ZES group compared with the SES group (6.5% vs. 25.7%, P=0.036), even though IVUS was performed only in 66 enrolled patients (41.3%). Until now, late-acquired ISA has not been proven to be associated with late ST in the DES era. 29, 30 Recently, Cook et al reported that late-acquired ISA was seen to occur quite frequently on IVUS in patients presenting with ST after implantation of DES. 31 A large-scale meta-analysis also showed that the risk of late-acquired ISA strongly increased after DES implantation as compared with BMS, and was associated with late and very late ST. 32 Therefore, additional large-scale randomized studies with longer observation periods are needed to clarify this issue.
Study Limitations
There were several limitations in this study. First, this study used a non-inferiority design to compare the angiographic surrogate endpoint of in-segment binary restenosis rate between 2 DES. Although the number of enrolled patients was calculated with reference to those from the previous studies, 8,9,12 additional large-scale randomized studies are needed to reach a definite conclusion on the superiority of angiographic outcomes between the 2 stents. Second, only 41% of patients underwent follow-up IVUS at 9 months because it was not mandated by protocol. This may have introduced selection bias into the IVUS findings, therefore the results must be interpreted with this in mind. Finally, this study was singleblinded, and the identity of the treatment stent was known to the interventional operator, which could have introduced bias into procedural outcomes and the performance of repeat revascularization.
